我们的目标是评估SARC-F,SARC-CalF,SARC-F-EBM,小腿周长(CC),上臂中围(MUAC)和Ishii检验可用于精神分裂症患者的肌肉减少症的准确筛查。
我们招募了50岁或以上的精神分裂症患者,他们经常服用抗精神病药物,在两个心理健康中心。使用InBody770仪器分析基于生物阻抗的肌肉质量,而肌肉力量是用数字握力测力计测量的。根据患者超过6m的步态速度来衡量患者的身体表现。使用标准AWGS2019诊断标准,灵敏度表明了六种筛选方法的准确性,负预测值(NPV),和接收器工作特征曲线下面积(AUC)。
共纳入339例稳定期精神分裂症患者。肌少症的总患病率为53.1%,患病率分别为55.6%和47.66%,分别,对于男性和女性。总人群中肌肉减少症的患病率为16.22%,男性和女性的比例分别为18.97%和10.28%,分别。SARC-F,SARC-CalF,SARC-F-EBM,CC,MUAC和Ishii试验敏感性/NPV分别为41.86%/0.52、79.07%/0.7、28.68%/0.51、78.3%/0.71、76.74%/0.7、89.92%/0.84,男性分别为45.1%/0.59、94.12%/0.91、54.9%/0.7、92.16%/60.91、74.51%/0.77、96.08%/0.94,在女性。在男性中,SARC-F的AUC,SARC-CalF,SARC-F-EBM,CC,MUAC和Ishii测试为0.601(95CI,0.528-0.673),0.754(95CI,0.69-0.817),0.657(95CI,0.588-0.727),0.8(95CI,0.744-0.856),0.781(95CI,0.721-0.84)和0.88(95CI,0.837-0.922),分别,在女性中,他们是0.587(95CI,0.479-0.696),0.794(95CI,0.709-0.878),0.799(95CI,0.71-0.888),0.893(95CI,0.833-0.953),0.843(95CI,0.772-0.915)和0.855(95CI,0.784-0.926),分别。
精神分裂症患者中肌肉减少症的患病率很高。临床医生应筛查精神分裂症患者的肌少症,并及时提供干预措施,以减少不良事件的发生。以上六种工具可以作为筛选工具,Ishii测试是最适合筛查的。
Our objective was to evaluate if SARC-F, SARC-CalF, SARC-F-EBM, calf circumference (CC), mid-upper-arm circumference (MUAC) and Ishii test can be used to accurately screen for sarcopenia in schizophrenic patients.
We enrolled schizophrenic patients aged 50 or older, who were regularly taking antipsychotic medications, at two mental health centres. Bioimpedance-based muscle-mass was analysed with an InBody 770 instrument, while muscle strength was measured with a digital grip-strength dynamometer. The physical performance of the patients was gauged from their gait speed over 6 m. Standard AWGS2019 diagnostic criteria were used, and the accuracies of the six screening methods were indicated by the sensitivity, negative predictive value (NPV), and area under receiver operating characteristic curve (AUC).
A total of 339 stable schizophrenic patients were enrolled. The overall prevalence of sarcopenia was 53.1%, and the prevalence was 55.6% and 47.66%, respectively, for males and females. The prevalence of sarcopenia obesity in the total population was 16.22%, and that of males and females was 18.97% and 10.28%, respectively. The SARC-F, SARC-CalF, SARC-F-EBM, CC, MUAC and Ishii test sensitivity/NPV in screening for sarcopenia were 41.86%/0.52, 79.07%/0.7, 28.68%/0.51, 78.3%/0.71, 76.74%/0.7, 89.92%/0.84, respectively, in males and 45.1%/0.59, 94.12%/0.91, 54.9%/0.7, 92.16%/60.91, 74.51%/0.77, 96.08%/0.94, respectively, in females. In males, the AUCs of the SARC-F, SARC-CalF, SARC-F-EBM, CC, MUAC and Ishii test were 0.601 (95%CI, 0.528-0.673), 0.754 (95%CI,0.69-0.817), 0.657 (95%CI,0.588-0.727), 0.8 (95%CI, 0.744-0.856), 0.781 (95%CI, 0.721-0.84) and 0.88 (95%CI, 0.837-0.922), respectively, and in females, they were 0.587(95%CI,0.479-0.696), 0.794 (95%CI,0.709-0.878), 0.799 (95%CI,0.71-0.888), 0.893 (95%CI, 0.833-0.953), 0.843 (95%CI, 0.772-0.915) and 0.855 (95%CI, 0.784-0.926), respectively.
The prevalence of sarcopenia in schizophrenic patients is high. Clinical doctors should screen for sarcopenia in schizophrenic patients and provide timely interventions to reduce the occurrence of adverse events. The above six tools can be used as screening tools, and the Ishii test is the most suitable for screening.